What happened

After DexCom (NASDAQ:DXCM) reported preliminary fourth-quarter and full-year results for 2018, its shares rallied 11.8% higher at 3:30 p.m. EST on Monday. 

So what

The leading manufacturer of continuous glucose monitors (CGM) used to monitor blood sugar levels in diabetics unveiled preliminary financial results for last quarter and the full year at the J.P. Morgan Healthcare Conference earlier today. 

A man in a suit flies into the air wearing a jet pack.


The company expects to deliver $331 million in sales for Q4, up at least 50% year over year and significantly higher than the consensus Wall Street analyst estimate of $285 million. For the full year, revenue is forecast to exceed $1.025 billion, up over 42% from 2017. Additionally, it's guiding for revenue to increase 15% to 20% to between $1.175 billion to $1.225 billion in 2019. For perspective, analysts were projecting $1.18 billion in sales in 2019.

The results reflect rising demand for its G6 CGM, a device that won approval last spring and that's included as part of Tandem Diabetes (NASDAQ:TNDM) t:slim X2 automated insulin delivery solution. Tandem's system relies on its t:slim X2 pump, DexCom's G6 CGM, and a sophisticated algorithm to automatically control insulin dosing based on real-time blood sugar data. 

Now what

DexCom will report official results on Feb. 21 after the market closes, but it's unlikely that those figures will differ materially from the preliminary results reported today.

The ability to automatically track blood sugar and dose insulin is a game-changing advance because it may help delay disease progression by helping patients remain within their desired glucose range more often. Currently, DexCom's only available with Tandem's automatic solution, but that could change in the future because it's also expected to be included in solutions being developed by insulin drug developer Eli Lilly & Co. (NYSE:LLY) and insulin pump maker Insulet (NASDAQ:PODD)

Also, DexCom is working on next-generation CGMs it's developing with Verily, a healthcare company backed by Alphabet. If those CGMs are cost-effective, it could expand DexCom's market beyond type 1 diabetics to type 2 patients who require multiple daily injections. A development like that would be significant given 30 million people have type 2 diabetes compared to 1.25 million with type 1 diabetes.

Check out the latest DexCom earnings call transcript. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.